Arrowhead Pharmaceuticals: Hold Rating Amid Redemplo Launch and Financial Stability

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Arrowhead Pharmaceuticals today and set a price target of $48.00.

Michael Ulz has given his Hold rating due to a combination of factors surrounding Arrowhead Pharmaceuticals’ recent developments. The company has launched Redemplo for familial chylomicronemia syndrome (FCS) with positive initial feedback, but the small patient population and the lack of sales guidance for 2026 suggest limited immediate financial impact. Additionally, while the approval of Redemplo sets the stage for potential label expansion into severe hypertriglyceridemia (SHTG), the success of ongoing Phase 3 trials remains to be seen.
Moreover, Arrowhead’s financial position is stable with substantial cash reserves, but the market’s response to the pricing strategy and the actual uptake of Redemplo will be crucial for future growth. The anticipation of milestone payments and upcoming data releases also contribute to a cautious outlook. Therefore, the Hold rating reflects a balanced view of both the opportunities and uncertainties facing Arrowhead Pharmaceuticals at this juncture.

According to TipRanks, Ulz is a 3-star analyst with an average return of 2.2% and a 43.71% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Kyverna Therapeutics, Inc., and Alnylam Pharma.